Prana Biotechnology’s compound could halt Alzheimer’s pathology
Women living in the most deprived areas of England are nearly twice as likely to be diagnosed with cervical cancer than their affluent counterparts - according to a report presented by national cancer director Professor Mike Richards at the Britain Against Cancer conference today (Tuesday). The report, published by the National Cancer Intelligence Network (NCIN),
Full Post: Living in deprived areas of England doubles cervical cancer risk
Prana Biotechnology has announced that a recent independent study conducted by Massachusetts General Hospital (MGH) has demonstrated that the Company’s Metal-Protein Attenuating Compounds (MPACs) could halt Alzheimer’s pathology.
The study published in the November edition of Annals of Neurology shows that the administration of the anesthetic gas isoflurane can spur the production of amyloid-beta protein, which causes plaques in the brains of Alzheimer’s patients. A group of mice in the study treated with clioquinol, also known as PBT1 and the predecessor of Prana’s compound PBT2, prior to receiving the isoflurance, had significant lower levels of the enzyme that leads to amyloid-beta production.
Geoffrey Kempler, Chairman and CEO of Prana, said, “Although PBT1 has now been superseded by PBT2 and is no longer being developed, we are happy that once again our underlying technology has demonstrated strong benefits in the fight against Alzheimer’s.”
Rudolph E. Tanzi, the study’s senior author, Director of the Genetics and Aging Research Unit at Mass. General, and Prana’s Co-Founding Scientist, said, “The new findings suggest that post-operative cognitive dysfunction and delirium may be related to increased amyloid beta protein levels driven by the commonly-used anesthetic, isoflurane. The fact that pretreatment with PBT1, which blocks amyloid beta protein accumulation, helped reduce the extent of neuronal cell death in the isoflurane-treated animals suggests that this class of drugs, which includes PBT2, might be considered as a prophylactic for mitigating the potential adverse effects of isoflurane during surgery. It must be emphasized, however, that all of these results have thus far been derived from mice studies and would therefore have to be first validated in humans.”
PBT2 is designed to have an improved safety and efficacy profile and has demonstrated significantly greater effectiveness in lowering plaque in Alzheimer patients.
“Studies conducted by noteworthy institutions such as MGH reaffirms our commitment to commercialize and develop the second generation of MPACs for the treatment of Alzheimer’s disease,” added Kempler.The study was also featured in the Boston Globe on November 12th. About Prana Biotechnology Limited
Prana Biotechnology was established to commercialize research into Alzheimer’s Disease and other major age-related neurodegenerative disorders. The Company was incorporated in 1997 and listed on the Australian Stock Exchange in March 2000 and listed on NASDAQ in September 2002. Researchers at prominent international institutions including The University of Melbourne, The Mental Health Research Institute (Melbourne) and Massachusetts General Hospital, a teaching hospital of Harvard Medical School, contributed to the discovery of Prana’s technology.
For the first time researchers have shown that a commonly used anesthetic can produce changes associated with Alzheimer’s disease in the brains of living mammals, confirming previous laboratory studies. In their Annals of Neurology report, which has received early online release, a team of Massachusetts General Hospital (MGH) investigators shows how administration of the gas
Full Post: Isoflurane induces Alzheimer’s-associated changes in mouse brains
Individuals with higher education levels appear to score higher on cognitive tests despite having evidence of brain plaques associated with Alzheimer’s disease, according to a report in the November issue of Archives of Neurology. The cognitive reserve hypothesis holds that individuals with greater cognitive (thinking, learning and memory) abilities are able to delay symptoms of
Full Post: Greater thinking, learning and memory abilities delay symptoms of Alzheimer’s disease
The only known genetic risk factor for Alzheimer’s disease slows down the brain’s ability to export a toxic protein known as amyloid-beta that is central to the damage the disease causes, scientists have found. The research, published Nov. 13 by the Journal of Clinical Investigation, provides new clues into the workings of a protein known
Full Post: Alzheimer’s gene slows brain’s ability to export toxic protein
Scientists say brain scans show that education appears to lessen the effects of Alzheimer’s disease. The scientists from the Washington University School of Medicine, St. Louis, say their research supports the ‘cognitive reserve’ hypothesis and individuals with levels of higher education levels score higher on cognitive tests despite having Alzheimer’s disease. According to the hypothesis,
Full Post: Education lessens the effects of Alzheimer’s
Australian scientists are suggesting that grape seeds may be a potential treatment in warding off Alzheimer’s disease. The scientists at Flinders University have found that adding grape seed extract to the diet prevented the formation of deposits of amyloid proteins in the brain. The discovery was made by a team of medical scientists in the
Full Post: Grape seeds could ward off Alzheimer’s